Oxycodone and acetaminophen

Percocet treats pain severe enough to require an opioid when alternatives are inadequate. Reserve it for alternatives that are ineffective, not tolerated or insufficient. Addiction, overdose and death can occur at any dose or duration; many acute conditions need only a few days when an opioid is necessary.

This profile covers current immediate-release oral Percocet tablets containing oxycodone hydrochloride plus 325 mg acetaminophen. It does not establish single-ingredient oxycodone, extended-release oxycodone, liquid or another combination product dosing. A fixed combination limits independent titration of the components.

For first opioid use, the label starts with 2.5 mg/325 mg tablets, 1–2 tablets every 6 hours as needed, at the lowest dose achieving adequate analgesia. The usual adult regimen for the other reviewed strengths is one tablet every 6 hours as needed. Individualize for prior exposure, pain and respiratory/addiction risk; do not self-escalate.

The table reproduces labeled maximal tablet counts and calculated acetaminophen totals, not a recommendation to reach them. Some ceiling counts exceed what the usual six-hour schedule supplies; do not change frequency to reach a ceiling. Follow the lower limit set by the prescription, clinical risks, product ceiling and total daily acetaminophen.

The product label requires total acetaminophen not to exceed 4,000 mg/day from all sources. Do not add another APAP-containing medicine without advice; check OTC cold/pain labels. This ceiling is not a universally safe target, especially with liver disease or alcohol use, and it does not authorize extra opioid tablets. Suspected excess requires immediate medical assessment even if the person feels well.

Reevaluate pain source, benefit, sedation/respiration and adverse effects before increasing. Worsening pain after an increase may reflect opioid-induced hyperalgesia rather than a need for more opioid. Relative bioavailability versus extended-release oxycodone is unknown in this label; conversion can cause excessive sedation/respiratory depression and needs a specific clinician plan.

Start below the usual dose in hepatic or renal impairment and titrate carefully while monitoring sedation, respiration and hypotension. Older adults should generally start low and titrate slowly. The label supplies no fixed eGFR, dialysis or Child-Pugh conversion table; the acetaminophen component also requires liver-risk assessment.

Do not abruptly stop or rapidly taper a physically dependent patient. Agree on an individualized taper and follow-up plan; the label illustrates reductions no greater than 10–25% of the total daily opioid dose every 2–4 weeks, with adjustments for duration, withdrawal, pain and mental health. This is not a compulsory universal schedule. A missed dose is followed by the next usual prescribed dose, not a double dose.

Significant respiratory depression; acute/severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known/suspected GI obstruction including paralytic ileus; or hypersensitivity to oxycodone, acetaminophen or another ingredient.

The current box covers addiction/abuse/misuse, life-threatening respiratory depression, accidental ingestion, benzodiazepine/CNS-depressant combinations, neonatal withdrawal, opioid REMS, CYP3A4 interactions and acetaminophen hepatotoxicity. These risks persist despite correct prescribing; assess, counsel and monitor rather than treating a labeled tablet ceiling as assurance of safety.

Frequently observed effects include dizziness/lightheadedness, sedation, nausea/vomiting, constipation and itching. Serious events include apnea/respiratory arrest, hypotension/shock, liver toxicity, anaphylaxis, serious skin reactions, serotonin syndrome and adrenal insufficiency. Prolonged opioid use may affect androgen levels/fertility. Postmarketing hypoglycemia and OIED are also reported; frequency/causality cannot be inferred from spontaneous reports.

Macrolides, azole antifungals and protease inhibitors can increase oxycodone exposure and fatal respiratory depression risk; combined CYP3A4/CYP2D6 inhibition may amplify effects. Adding an inducer such as rifampin/carbamazepine/phenytoin may reduce effect or provoke withdrawal; stopping an inducer can raise exposure. Starting/stopping either class needs frequent reassessment and clinician-directed dose adjustment.

Benzodiazepines, sedative-hypnotics, gabapentinoids, antipsychotics, other opioids, muscle relaxants and alcohol can produce profound sedation, hypotension, respiratory depression, coma or death. Reserve unavoidable combinations for inadequate alternatives, use the lowest effective doses/durations and provide rescue/caregiver education. Avoid alcohol, which also increases acetaminophen liver risk.

SSRIs/SNRIs, TCAs, tramadol, certain muscle relaxants and other serotonergic agents may cause serotonin syndrome; monitor during initiation/adjustment and stop/evaluate if suspected. Percocet is not recommended with MAOIs or within 14 days after stopping them, including relevant linezolid/methylene-blue exposures. Urgent exceptions require supervised specialist management, not a self-directed regimen.

Mixed agonist/antagonist or partial-agonist analgesics may reduce analgesia or precipitate withdrawal; opioid transitions need a clinician plan. Anticholinergics can worsen constipation/urinary retention/ileus; monitor symptoms. Opioids may blunt diuresis and affect pressure; monitor diuretic response. The label also describes acetaminophen interactions including reduced lamotrigine levels; review the complete list when relevant.

Use only after individualized benefit-risk assessment. Extended use in pregnancy can cause life-threatening neonatal opioid withdrawal requiring specialist management. Placental transfer can cause neonatal sedation/respiratory depression; the label does not recommend use during/immediately before labor when other analgesic techniques are more appropriate.

Both components enter milk. The current label reports low relative infant oxycodone exposure in a limited postpartum study but still requires observation for unusual sleepiness, breathing trouble or limpness and immediate care if these occur. Its <60 mg/day research statement is not a universal breastfeeding safety limit or dosing recommendation. Infant withdrawal can occur if maternal opioid therapy or breastfeeding stops.

Pediatric safety/effectiveness are not established. Older, cachectic/debilitated and chronic-lung-disease patients have greater respiratory-depression risk, even at recommended doses; consider alternatives and frequent reassessment when initiating/titrating.

Reduced clearance/prolonged half-life can increase opioid effects. Start lower and monitor sedation, respiration and pressure. Underlying liver disease and alcohol also raise APAP liver-injury risk; evaluate whether a fixed combination is appropriate rather than assuming a normal-dose APAP ceiling applies.

Oxycodone is a full opioid agonist with relative mu-receptor selectivity; respiratory-center depression and GI motility reduction accompany analgesia. Acetaminophen’s analgesic mechanism is incompletely established and thought to involve central actions. The absence of an oxycodone analgesic ceiling does not mean this fixed combination can be escalated without limit.

Oral oxycodone is substantially absorbed and metabolized to noroxycodone mainly through CYP3A and oxymorphone through CYP2D6, with subsequent conjugation. Organ impairment and pathway interactions can prolong effects; use actual response and monitoring rather than assuming equal exposure across patients.

Acetaminophen is rapidly absorbed, primarily glucuronidated/sulfated in the liver and excreted as metabolites through urine. A minor oxidative pathway creates a reactive metabolite normally detoxified by glutathione; overdose can cause delayed hepatic necrosis. Its labeled plasma half-life is about 1.25–3 hours and may lengthen with liver injury/overdose.

Reassess pain source, function, benefit, sedation/respiration, constipation, hypotension, interactions and signs of misuse/addiction. Check liver/renal risks and all APAP sources; worsening pain may require assessment for OIH rather than automatic escalation. Tapering needs ongoing care and mood/withdrawal monitoring.

Discuss an accessible opioid-overdose reversal agent, such as naloxone or nalmefene, with patient and caregivers; products differ in route, strength and approved ages. For suspected overdose, call emergency services even after reversal. Reversal may wear off before oxycodone does and repeat dosing/medical observation may be necessary under the rescue product instructions. Reversal does not treat acetaminophen liver injury.

Get immediate medical/poison-service help even before symptoms. Clinicians assess acetaminophen levels and the exposure history and use N-acetylcysteine promptly when indicated; delayed absorption or combination overdose may complicate interpretation. Do not apply a home treatment rule or wait for jaundice/liver pain.

Do not share, self-increase, mix with alcohol or drive until effects are known. Store securely away from children and visitors; even one accidental dose can be fatal. Prefer prompt take-back disposal; if unavailable, follow the current label/FDA instructions for this flush-listed opioid. Read the Medication Guide and know when constipation or sedation needs care.

Current Percocet 5 mg/325 mg is a blue round tablet marked PERCOCET and 5 on one side with a bisect on the other; 100-count NDC 63481-623-70. Current label manufacturing is for SpecGx with Par Health copyright; do not assume an older Endo company listing establishes the current package.

Oral IR tablets: 2.5/325, 5/325, 7.5/325 or 10/325 mg oxycodone hydrochloride/acetaminophen. Product strength is stated as the hydrochloride, not recalculated oxycodone base. All are Schedule II controlled substances. Different generic combinations or liquids require their own labels.

Store at 20–25°C, protect from moisture and dispense in a tight light-resistant container. Keep securely out of reach/sight of children and inaccessible to others; arrange prompt safe disposal when no longer needed.